Twist Bioscience Corporation Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Twist Bioscience Corporation (TWST) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $21.75 per share for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-03
- Twist Bioscience Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-12-31 was $19.48, a 11.89% increase year-over-year.
- Twist Bioscience Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-12-31 was $17.41, a 6.03% increase year-over-year.
- Twist Bioscience Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-12-31 was $16.42, a 4.37% decline year-over-year.
- Twist Bioscience Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2022-12-31 was $17.17.
- Twist Bioscience Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $19.31, a 4.38% increase from fiscal 2024.
- Twist Bioscience Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $18.50, a 58.12% increase from fiscal 2023.
- Twist Bioscience Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $11.70, a 5.80% decline from fiscal 2022.
- Twist Bioscience Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $12.42.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.75 10-Q · filed 2026-08-03 | |||
| 2026-03-31 | $22.44 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $19.48 10-Q/A · filed 2026-02-26 | |||
| 2025-09-30 | $19.31 10-K · filed 2025-11-17 | |||
| 2025-06-30 | $16.85 10-Q · filed 2025-08-04 | |||
| 2025-03-31 | $15.64 10-Q · filed 2025-05-05 | |||
| 2024-12-31 | $17.41 10-Q · filed 2025-02-03 | |||
| 2024-09-30 | $18.50 10-K · filed 2024-11-18 | |||
| 2024-06-30 | $19.85 10-Q · filed 2024-08-02 | |||
| 2024-03-31 | $17.88 10-Q · filed 2024-05-02 | |||
| 2023-12-31 | $16.42 10-Q · filed 2024-02-02 | |||
| 2023-09-30 | $11.70 10-K · filed 2023-11-21 | |||
| 2023-06-30 | $11.82 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $14.86 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $17.17 10-Q · filed 2023-02-07 | |||
| 2022-09-30 | $12.42 10-K/A · filed 2023-06-05 | |||
| 2019-09-30 | $6.67 10-K · filed 2019-12-13 | |||
| 2019-06-30 | $5.95 10-Q · filed 2019-08-09 | |||
| 2019-03-31 | $4.13 10-Q · filed 2019-05-02 | |||
| 2018-12-31 | $4.67 10-Q · filed 2019-02-11 | |||
| 2018-09-30 | $5.37 10-K · filed 2019-12-13 | |||
| 2017-09-30 | $5.54 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |